References
1 Feagan BG, Rutgeerts P, Sands BE, et al. Velolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013, 22;369(8):699-710. DOI: 10.1056/NEJMoa1215734
2 Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711–721. DOI: 10.1056/NEJMoa1215739
3 Rossi RE, Conte D, Massironi, S. Primary sclerosing cholangitis associated with inflammatory bowel disease: an update. Eur J Gastroenterol Hepatol 2016 Feb;28(2):123-13. DOI: 10.1097/MEG.0000000000000532.
4 Schnitzler F, Friedrich M, Stallhofer J, et al. Solid organ transplantation in patients with inflammatory bowel diseases (IBD): analysis of transplantation outcome and IBD activity in a large single center cohort. PLoS ONE 2015; 10: e0135807. DOI: 10.1371/journal.pone.0135807
5 Sandhu A, Alameel T, Dale CH, et al. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series. Aliment Pharmacol Ther 2012; 36: 159–165 DOI:10.1111/j.1365-2036.2012.05141.x
6 Mohabbat AB, Sandborn WJ, Loftus EV, et al. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. Aliment Pharmacol Ther 2012; 36: 569–74. DOI:10.1111/j.1365-2036.2012.05217.x
7 Meszaros M, Pageaux GP, Altwegg R. Management of ulcerative colitis using vedolizumab after liver transplantation for primary sclerosing cholangitis. J Crohns Colitis 2016; 10: 236. DOI:10.1093/ecco-jcc/jjv182
8 Muntaz S, Goh J, Hirschfield G, et al. Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab. Frontline Gastroenterol doi:10.1136/flgastro-2016-100711
9 Lim TY, Pavlidis P, Gulati S, et al. Vedolizumab in inflammatory bowel disease associated with autoimmune liver disease pre- and postliver transplantation: a case series. Inflamm Bowel Dis 2016; 22: E39–40. DOI:10.1097/MIB.0000000000000906
10 Hartery K, O´Reilly S. Houlihan D, et al. Letter: Vedolizumab for the managment of inflammatory bowel disease in patients after liver trasplantation for primary sclerosing colangitis. Aliment Pharmacol Ther 2017;45:373-379 DOI:10.1111/apt.13861